4.70
前日終値:
$4.72
開ける:
$4.51
24時間の取引高:
4.25M
Relative Volume:
1.29
時価総額:
$418.32M
収益:
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-19.38%
1か月 パフォーマンス:
-8.38%
6か月 パフォーマンス:
+21.76%
1年 パフォーマンス:
+141.03%
Atyr Pharma Inc Stock (ATYR) Company Profile
名前
Atyr Pharma Inc
セクター
電話
(858) 731-8389
住所
10240 SORRENTO VALLEY ROAD, SAN DIEGO
ATYR を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ATYR
Atyr Pharma Inc
|
4.70 | 420.10M | 0 | 0 | 0 | 0.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Atyr Pharma Inc Stock (ATYR) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2025-02-18 | 開始されました | Leerink Partners | Outperform |
2025-01-06 | 開始されました | Cantor Fitzgerald | Overweight |
2024-10-04 | 開始されました | Wells Fargo | Overweight |
2024-09-05 | 開始されました | Jefferies | Buy |
2023-07-05 | ダウングレード | Oppenheimer | Outperform → Perform |
2021-10-12 | 開始されました | RBC Capital Mkts | Outperform |
2021-09-21 | 開始されました | Piper Sandler | Overweight |
2021-05-10 | 開始されました | Laidlaw | Buy |
2020-08-17 | アップグレード | H.C. Wainwright | Neutral → Buy |
2020-03-04 | 開始されました | ROTH Capital | Buy |
2020-03-02 | 開始されました | Oppenheimer | Outperform |
2018-02-14 | ダウングレード | JP Morgan | Neutral → Underweight |
2017-09-07 | 開始されました | Piper Jaffray | Overweight |
2016-12-13 | ダウングレード | JP Morgan | Overweight → Neutral |
2015-12-16 | 開始されました | Citigroup | Neutral |
2015-06-01 | 開始されました | Citigroup | Buy |
2015-06-01 | 開始されました | JP Morgan | Overweight |
すべてを表示
Atyr Pharma Inc (ATYR) 最新ニュース
Martin Shkreli Is Shorting This ‘Strong Buy’ Penny Stock. How Should You Play Shares Here? - Yahoo Finance
Price Channel Expanding on aTyr Pharma Inc.’s ChartReal Time Stock Movement Analysis Indicates Breakout - metal.it
Analysts Offer Insights on Healthcare Companies: Exelixis (EXEL), aTyr Pharma (ATYR) and HCA Healthcare (HCA) - The Globe and Mail
Price Consolidation Hints at Upcoming Move in aTyr Pharma Inc.Swing Trading Entry Signals Suggest Opportunity Zone - metal.it
Wyckoff Accumulation Phase Possible in aTyr Pharma Inc.Entry Plan for Oversold Reversal Stocks Released - metal.it
Will aTyr Pharma Inc. Recover After Recent DeclineMarket Momentum Signal Generator Shows Trends - metal.it
aTyr Pharma Inc put volume heavy and directionally bearish - TipRanks
Published on: 2025-07-29 07:01:04 - beatles.ru
aTyr Pharma Inc. Breakout Confirmed by Volume MetricsWatchlist for Smart Swing Trading Updated - metal.it
What makes aTyr Pharma Inc. stock price move sharplyTrend Analysis for Safer Trades Gains Popularity - metal.it
aTyr Pharma Stock Faces Market Scrutiny Amid Financial Challenges - StocksToTrade
aTyr Pharma Inc. Company’s Quarterly Earnings Growth: What the Numbers SayMarket Entry and Exit Point Tips From Traders - metal.it
What is aTyr Pharma Inc. company’s growth strategyMaximize returns with data-driven strategies - jammulinksnews.com
Is it the right time to buy aTyr Pharma Inc. stockAchieve breakthrough gains with smart trades - jammulinksnews.com
What are the technical indicators suggesting about aTyr Pharma Inc.Free Consultation - jammulinksnews.com
How does aTyr Pharma Inc. generate profit in a changing economyFree Stock Recommendation For Fast Growth - jammulinksnews.com
What are aTyr Pharma Inc. company’s key revenue driversGet daily updates on the hottest stocks - jammulinksnews.com
How volatile is aTyr Pharma Inc. stock compared to the marketUnstoppable trading performance - jammulinksnews.com
Is aTyr Pharma Inc. a good long term investmentUnprecedented market success - PrintWeekIndia
Does aTyr Pharma Inc. stock pay reliable dividendsHigh-performance investment picks - jammulinksnews.com
RNA Therapeutics and Vaccines Market Industry Trends & Forecasts to 2035, with Profiles of Alphavax, Arcturus Therapeutics, aTyr Pharma, Gritstone Bio, HDT Bio, MiNA Therapeutics, & VLP TherapeuticsResearchAndMarkets.com - FinancialContent
GE Vernova Posts Better-Than-Expected Earnings, Joins Thermo Fisher Scientific, Lennox International, General Dynamics And Other Big Stocks Moving Higher On Wednesday - Benzinga
aTyr Pharma Soars 11.26% on Phase 3 Study Completion - AInvest
aTyr Pharma stock holds Buy rating as Phase 3 trial completes - Investing.com Canada
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout - TipRanks
What analysts say about aTyr Pharma Inc. stockMarket-leading capital gains - Autocar Professional
aTyr Pharma Announces Last Patient Visit in Phase 3 - GlobeNewswire
What drives aTyr Pharma Inc. stock priceMarket-beating returns - jammulinksnews.com
aTyr Pharma Inc. Stock Analysis and ForecastFree Risk Assessment Services - jammulinksnews.com
aTyr Pharma announces last patient visit in Phase 3 EFZO-FIT study - TipRanks
First-Ever Global Phase 3 Trial for Sarcoidosis Treatment Reaches Major Milestone with 268 Patients - Stock Titan
Atyr Pharma Inc (ATYR) 財務データ
Atyr Pharma Inc (ATYR) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Atyr Pharma Inc (ATYR) インサイダートレーディング
インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
---|---|---|---|---|---|---|---|
Broadfoot Jill Marie | Chief Financial Officer |
Feb 04 '25 |
Sale |
3.78 |
1,254 |
4,740 |
31,763 |
DENYES NANCY | General Counsel |
Feb 04 '25 |
Sale |
3.78 |
899 |
3,398 |
26,555 |
大文字化:
|
ボリューム (24 時間):